MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Abexinostat

CAS No. : 783355-60-2

MCE 国际站：Abexinostat

产品活性：Abexinostat (CRA 024781) 是一种新的泛 HDAC 抑制剂，主要靶向 HDAC1 的 K_i 值为 7 nM。Abexinostat 也抑制 MBLAC2 水解酶活性，EC₅₀ 小于 10 nM。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：HDAC

In Vitro: Abexinostat (CRA 024781) exhibits potent antitumor activity against a variety of tumor cell lines with GI_50% ranging from 0.15 μM to 3.09 μM. Abexinostat (CRA 024781) also has an antiproliferative effect on HUVEC endothelial cells with GI_50% of 0.43 μM. Abexinostat (CRA 024781) treatment causes dose-dependent accumulation of both acetylated histones and acetylated tubulin in HCT116 or DLD-1 cells, induces expression of p21, and leads to PARP cleavage and accumulation of the γH2AX. Inhibition of HDAC enzymes by Abexinostat (CRA 024781) leads to a significant reduction in the transcription of genes specifically associated with HR, including RAD51. Consistent with inhibition of HR, Abexinostat (CRA 024781) treatment results in a decreased ability to perform homology directed repair of I-SceI-induced chromosome breaks in transfected CHO cells. Abexinostat (CRA 024781) induces S phase depletion, G2 cell cycle arrest, and apoptosis in soft tissue sarcoma (STS) cells. Abexinostat (CRA 024781) induces Rad51 transcriptional repression in STS cells potentially mediated via enhanced E2F1 binding to the Rad51 proximal promoter.

In Vivo: Abexinostat (CRA 024781) parenterally administered to mice harboring HCT116 or DLD-1 colon tumor xenografts results in a statistically significant reduction in tumor growth. Inhibition of tumor growth is accompanied by an increase in the acetylation of α-tubulin in peripheral blood mononuclear cells, and an alteration in the expression of many genes in the tumors, including several involved in apoptosis and cell growth.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  YF479  |  KD 5170  |  HDAC-IN-48  |  Remetinostat  |  HDAC-IN-30  |  HDAC-IN-52  |  CG347B  |  Psammaplin A  |  JPS016  |  HDAC6-IN-9  |  Splitomicin  |  TNG260  |  Tacedinaline  |  G4/HDAC-IN-1  |  HPOB  |  Tubacin  |  HDAC-IN-37  |  Vorinostat-d5  |  Resminostat  |  MAO A/HDAC-IN-1  |  NCC-149  |  Tubulin/HDAC-IN-1  |  PI3K/HDAC-IN-1  |  HDAC1-IN-4  |  HDAC6/HSP90-IN-1  |  Entinostat-d₄  |  UF010  |  MOCPAC  |  Ivaltinostat  |  HDAC-IN-56

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。